eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2026-09-30 19 3 2316 2326 10.13005/bpj/3495 73283 article Development and In Vitro Assessment of Novel Bilayer Tablets Containing Glimepiride and Metformin Lakshmana Rao Atmakuri 1 Rajani Vetapalem 2 Eswara Gopala Krishna Murthy Talasila 3 Haritha Potluri 4 Ramesh Alluri 5 Vijaya Kumar Ghanta 6 Department of Pharmaceutical Analysis, V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh, India. Department of Pharmaceutics, V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh, India. Department of Pharmaceutics, Bapatla College of Pharmacy, Bapatla, Andhra Pradesh, India Department of Chemistry, Seshadri Rao Gudlavalleru Engineering College, Gudlavalleru, Andhra Pradesh, India. Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research, Narsapur, Telangana, India. Department of Pharmacy Practice, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India. Type 2 diabetes mellitus requires combination therapy to achieve effective glycemic control. Bilayer tablet formulations combining immediate and sustained drug release offer improved therapeutic outcomes. Glimepiride and Metformin hydrochloride are commonly prescribed together due to their complementary mechanisms of action. The aim of the current research was to formulate bilayer tablets of Glimepiride and Metformin hydrochloride to enhance therapeutic utility in the management of type 2 diabetes mellitus. Bilayer tablets were developed with Glimepiride in the immediate-release layer using the superdisintegrant croscarmellose sodium, and Metformin hydrochloride in the sustained-release layer using microcrystalline cellulose and HPMC K100M as key excipients. The formulations were optimized by evaluating immediate-release characteristics of Glimepiride and sustained-release profiles of Metformin hydrochloride. The optimized formulation (F6) demonstrated 99.92% immediate release of Glimepiride within 45 minutes, while Metformin hydrochloride showed a sustained release of 99.87% over a period of 12 hours. The study indicates the successful development of bilayer tablets of Glimepiride and Metformin hydrochloride, which can be effectively used for the management of type 2 diabetes mellitus. https://biomedpharmajournal.org/vol19no3/development-and-in-vitro-assessment-of-novel-bilayer-tablets-containing-glimepiride-and-metformin/ Bilayered tablets Diabetes mellitus Evaluation Glimepiride Insulin Metformin